GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Drugs Made In America Acquisition II DMII · USD

N/A · US listing · 🇺🇸 United States

Compare

10.23

+0.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

$4.2m

FY2024FY2025

Free cash flow

−$1.0m

FY2024FY2025

Shareholders' equity

$487.2m

FY2024FY2025

Income statement

Fiscal years

FY2025FY2024
Operating income−$1.3m−$151,719
Net income$4.2m−$151,719
Diluted earnings per share0.07-0.00

Balance sheet

At each fiscal year end

FY2025FY2024
Total assets$505.0m$138,064
Cash and short-term investments$223$17,035
Total liabilities$17.8m$254,783
Debt—$250,100
Shareholders' equity$487.2m−$116,719
Shares outstanding64m64m

Cash flow

Fiscal years

FY2025FY2024
Cash from operations−$1.0m−$194,299
Free cash flow−$1.0m−$194,299

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Sept 2024
Operating income−$112,227−$132,030−$1.0m−$155,513−$38,073−$59,327−$41,684
Net income$4.4m$4.3m$4.3m−$46,158−$38,073−$59,327−$41,684
Diluted earnings per share0.090.090.07-0.00-0.00-0.00-0.00
Total assets$514.1m$509.7m$505.0m$501.0m$113,395$105,095—
Cash and short-term investments$174,974$347,720—$315,087$4,394$6,991—
Debt—$450,000——$297,292$250,100—
Shareholders' equity−$17.9m$491.6m$487.2m$482.8m−$214,119−$176,046—

Valuation history

At each fiscal year end

FY2025
Price to earnings150.6

Share price return

Finished calendar years

2025
Return-0%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.